124 related articles for article (PubMed ID: 7303836)
21. A double-blind trial of O-(beta-hydroxyethyl)-rutoside in patients with chronic venous insufficiency.
Bergqvist D; Hallböök T; Lindblad B; Lindhagen A
Vasa; 1981; 10(3):253-60. PubMed ID: 7025500
[No Abstract] [Full Text] [Related]
22. [Anti-edema activity of injectable Venoruton in abdominal surgery].
De Anna D; Liboni A; Paoli M; Pollinzi V; Malin L; Mannella P; Ambroso G; Oberhauser V
Minerva Chir; 1979 Oct; 34(20):1377-92. PubMed ID: 503345
[TBL] [Abstract][Full Text] [Related]
23. [Effect of 0-(beta-hydroxyethyl)-rutoside (Venoruton) on symptomatic venous insufficiency in the lower limbs].
Pedersen FM; Hamberg O; Sørensen MD; Neland K
Ugeskr Laeger; 1992 Sep; 154(38):2561-3. PubMed ID: 1413183
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of mono-3'- and mono-4'-0-(beta-hydroxyethyl)-rutoside derivatives, after single doses of Venoruton powder in healthy volunteers.
Kienzler JL; Sallin D; Schifflers MH; Ghika A
Eur J Clin Pharmacol; 2002 Sep; 58(6):395-402. PubMed ID: 12242598
[TBL] [Abstract][Full Text] [Related]
25. o-(beta-Hydroxyethyl)-rutoside-mediated protection of renal injury associated with cis-diamminedichloroplatinum(II)/hyperthermia treatment.
Bull JM; Strebel FR; Sunderland BA; Bulger RE; Edwards M; Siddik ZH; Newman RA
Cancer Res; 1988 Apr; 48(8):2239-44. PubMed ID: 3349489
[TBL] [Abstract][Full Text] [Related]
26. [Prevention of radiation-induced skin reactions in breast cancer].
Pischnamazzadeh M
Strahlentherapie; 1983 Jan; 159(1):9-12. PubMed ID: 6340249
[TBL] [Abstract][Full Text] [Related]
27. [Pharmacolymphography with Venalot and Venoruton--a 7 years' report].
Schmidt F; Keilacker M
Radiol Diagn (Berl); 1985; 26(1):41-51. PubMed ID: 3991896
[No Abstract] [Full Text] [Related]
28. New pharmacological and clinical properties of the venoactive agent: Venoruton (Paroven). Studies presented at the 1st Mediterranean Congress of Angiology. Corfu, Greece, May 29 to June 3, 1988. Abstracts.
Int Angiol; 1988; 7(4 Suppl):1-16. PubMed ID: 3249081
[No Abstract] [Full Text] [Related]
29. Spectrophotofluorometric analysis of 3',4',7-tris[O-(beta-hydroxyethyl)]rutoside in urine.
Tan HS; Mowery PJ; Ritschel WA; Neu C
J Pharm Sci; 1978 Aug; 67(8):1142-4. PubMed ID: 671254
[TBL] [Abstract][Full Text] [Related]
30. [Dose-response study with O-(beta-hydroxyethyl)-rutoside oral solution].
Nocker W; Diebschlag W
Vasa; 1987; 16(4):365-9. PubMed ID: 3321740
[No Abstract] [Full Text] [Related]
31. Rutoside and the X-ray induced damage in jejunal mucosa of mouse.
Rao KR; Fritz-Niggli H
Strahlentherapie; 1984 Oct; 160(10):624-6. PubMed ID: 6388050
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the microcirculatory effects of Venoruton in patients with chronic venous hypertension by laserdoppler flowmetry, transcutaneous PO2 and PCO2 measurements, leg volumetry and ambulatory venous pressure measurements.
Belcaro G; Rulo A; Candiani C
Vasa; 1989; 18(2):146-51. PubMed ID: 2662674
[TBL] [Abstract][Full Text] [Related]
33. The effect of O-(beta-hydroxyethyl)-rutosides on function and structure of the ganglion cells.
Blasius W; Leusser K; Merker G
Arzneimittelforschung; 1976; 26(9):1645-50. PubMed ID: 1036693
[TBL] [Abstract][Full Text] [Related]
34. [Venoruton and capillary permeability].
Cesarone MR; Laurora G; Gabini M; Errichi BM; Candiani C; Belcaro G
Minerva Cardioangiol; 1989 May; 37(5):265-8. PubMed ID: 2779806
[TBL] [Abstract][Full Text] [Related]
35. [Clinical, placebo-controlled double-blind study of venoruton in the treatment of chronic venous insufficiency. Importance of the selection of patients].
Balmer A; Limoni C
Vasa; 1980; 9(1):76-82. PubMed ID: 7368843
[No Abstract] [Full Text] [Related]
36. Effects of some semisynthetic rutoside derivatives on human platelets.
Kahlé LH; Dannijs GJ; Ten Cate JW
Bibl Anat; 1975; 13():263-4. PubMed ID: 1231745
[No Abstract] [Full Text] [Related]
37. [Effect of Venoruton on the lower-leg volume in normal persons and in patients with venous-flow disorders].
Bopp J
Med Welt; 1977 Oct; 28(41):1660-4. PubMed ID: 927128
[No Abstract] [Full Text] [Related]
38. O-(beta-hydroxyethyl)-rutosides (Paroven; Venoruton): new studies, improved safety, and novel cardiovascular applications.
Cesarone MR; Belcaro G; Grossi MG
Angiology; 2008; 59 Suppl 1():5S-6S. PubMed ID: 18287161
[No Abstract] [Full Text] [Related]
39. Effect of HR (O-(beta-hydroxyethyl)-rutosides) on the impaired venous function of young females taking oral contraceptives. A strain gauge plethysmographic and clinical open controlled study.
Forconi S; Guerrini M; Pecchi S; Cappelli R; Bruni F
Vasa; 1980; 9(4):324-30. PubMed ID: 7008418
[TBL] [Abstract][Full Text] [Related]
40. Effect of o-(beta-hydroxyethyl)-rutoside in lymphangiography.
Broks PD
AJR Am J Roentgenol; 1977 Feb; 128(2):263-5. PubMed ID: 401613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
